CN105030748A - Taurine potassium-magnesium compound and preparation method thereof - Google Patents
Taurine potassium-magnesium compound and preparation method thereof Download PDFInfo
- Publication number
- CN105030748A CN105030748A CN201510475025.1A CN201510475025A CN105030748A CN 105030748 A CN105030748 A CN 105030748A CN 201510475025 A CN201510475025 A CN 201510475025A CN 105030748 A CN105030748 A CN 105030748A
- Authority
- CN
- China
- Prior art keywords
- taurine
- potassium
- magnesium
- ion
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a taurine potassium-magnesium compound and a preparation method and application thereof. The compound comprises potassium ions, magnesium ions and taurine. The molar ratio of the potassium ions, the magnesium ions and the taurine is (1-8):(1-4):(3-16). The compound can be prepared into various kinds of preparation acceptable in pharmacy, and is mainly used for resisting acute cerebral infarction, coronary heart disease, angina, migraine and the like.
Description
Technical field
The invention belongs to medicine field, especially relate to a kind of for the hearts, the brain organ-tissue ischemic injuries disease taurine potassium magnesium compositions having significant curative effect and preparation method thereof such as acute cerebral infarction, coronary heart diseases and angina pectoris and migraine.
Background technology
Along with the change of environment and the quickening of rhythm of life, increasing people endures the misery of the hearts such as acute cerebral infarction, coronary heart diseases and angina pectoris and migraine, brain organ-tissue ischemic injuries disease to the fullest extent, but does not have the above-mentioned disease of highly effective method prevention and therapy on the market at present.
Taurine content in natural marine organisms is the highest; a kind of can directly extraction or the small-molecule substance of synthetic from animals and plants; taurine is one of necessary 18 seed amino acids of human body; it is the simple sulfur-containing amino acid of a kind of chemical constitution; for alpha-amido ethyl sulfonic acid; do not participate in protein composition and metabolism, but exist in a free form or form complex with bile acid.Taurine participates in a series of physiological processes in vivo; as being combined, regulating osmotic pressure, the removing toxic substances of xenobiontics, stable, cell calcium flow adjustment, neurodevelopment, the nerve excitability adjustment of cell membrane, neuroprotective, antioxidation and arrhythmia etc. with bile acid; there is biological activity widely; good regulating action is played to systems such as blood vessel, nerve, muscular movement, endocrine, immunity, has important effect to infant brain and visual development especially.
In the market usual by taurine for the preparation of functional beverage.As Chinese patent CN101953503 " a kind of preparation technology of taurine beverage " disclose a kind of with rice, Oryza glutinosa through liquid fermentation, distillation after produce be rich in several amino acids, lactobacillus active nutrient liquid for primary raw material; science adds the preparation technology of the formulated taurine beverage of the nutrition enhancer such as taurine, inositol; prepared taurine beverage comprises active nutrient liquid, taurine, inositol etc., is also rich in the functional beverage of several amino acids and probiotics.
Taurine is preparing the application on medicine normally as auxiliary agent.As Chinese patent CN101062027 " compositions of the medicine of taurine and treatment cardiovascular and cerebrovascular disease " discloses a kind of pharmaceutical composition for the preparation for the treatment of cardiovascular and cerebrovascular disease; the parts by weight making the crude drug of this pharmaceutical composition consist of: taurine 500-15000 part, sodium tanshinone IIA sulfate 2-50 part.The pharmaceutical composition that the medicine for the treatment of cardiovascular and cerebrovascular disease by taurine and at least one of effective dose is made; treatment cardiovascular and cerebrovascular disease is of great importance; but more be medicine at performance therapeutical effect; wherein the cure mechanism of taurine is indefinite, does not also carry out experiment at human body and show that data are investigated.
Magnesium is the mineral element of needed by human, more at the content of human body, is called as the macroelement of human body.Chinese patent CN103404875 " a kind of composite marine special dietary food edible for cardiovascular patient " discloses a kind of nutriture that comprehensively can improve cardiovascular patient, strengthen the immunity of organisms of cardiovascular patient, improve the symptom of cardiovascular disease and reduce the incidence rate of Coronary Artery Disease Complicated disease, wherein magnesium is just as macroelement, is more that oligochitosan plays a role.
In sum, yet there are no now a kind of using the principle active component of taurine as Cardiovarscular on the market, be combined with potassium ion and magnesium ion and formed for adjusting biological metabolism, effectively treating the compositions of the organ-tissue such as the heart, brain ischemic injuries disease.
Summary of the invention
In order to solve the problem, the invention provides a kind of for effectively adjusting biological metabolism, to the organ-tissue such as the heart, brain ischemic injuries disease taurine potassium magnesium compositions having significant curative effect and preparation method thereof.
The technical solution adopted for the present invention to solve the technical problems is: a kind of taurine potassium magnesium compositions, is made up of potassium ion, magnesium ion and taurine.
Further, the mol ratio of the potassium ion in compositions, magnesium ion and taurine is (1-8): (1-4): (3-16).Be prepared in this ratio, reaction efficiency is high, and the yield of target product is higher.
Further, the mol ratio of the potassium ion in compositions, magnesium ion and taurine is 2:1:4.When carrying out reaction preparation in this ratio, energy consumption of reaction is minimum, and yield is the highest, and according to Medical Biochemistry, it can press the metabolism of optimal proportion usefulness in vivo.
Reaction equation of the present invention is:
KOH+C
2H
6NO
3SH＝KC
2H
6NO
3S+H
2O
Mg(OH)
2+2C
2H
6NO
3SH＝Mg(C
2H
6NO
3S)
2+2H
2O
2KOH+Mg(OH)
2+4C
2H
6NO
3SH＝2KC
2H
6NO
3S+Mg(C
2H
6NO
3S)
2+4H
2O
On market, existing taurine, potassium chloride salt, magnesium sulfate salt are applied to clinical as OTC (over-the-counter) and prescription drugs.
Taurine belongs to EAA antagonists, plays an important role in control ischemical reperfusion injury.
Potassium ion is as one of most important cation of human body, and be the material base maintaining cell membrane resting potential, it is poor to potassium concn inside and outside the permeability of potassium and film that resting potential depends mainly on cell membrane, and this current potential is the excitatoty key factor of muscular tissue that affects the nerves.Potassium participates in multiple metabolic processes, substantial connection is had with glycogen and protein synthesis, some enzymes relevant with carbohydrate metabolism in cell, high potassium concentration must be had to exist just to have and invigorate blood circulation as phosphorylase with containing sulfydryl enzyme etc., regulate osmotic pressure and the acid-base balance of fluid of inside and outside cell, (be about extracellular 20 times) because a large amount of potassium ion is present in cell, not only maintain osmotic pressure and the acid-base balance of intracellular fluid, also affect osmotic pressure and the acid-base balance of extracellular fluid.Potassium ion is the dominant cation of intracellular fluid, and in body, the potassium of 98% is present in cell.Cardiac muscle and neuromuscular all need the potassium concentration of relative constancy to maintain normal irritability.It contributes to maintaining neurological health, heart beating rule is normal, can prevention of stroke, and assists muscle normal contraction.
Magnesium ion, as one of most important cation of human body, is a kind of blocker of inorganic calcium ion channel, prevents intracellular calcium overload, can block the formation of the free radical that Reperfu-sion causes, can reduce the blood vessel injury after ischemia-reperfusion and myocardial damage.Magnesium ion helps cardiac muscle to rebuild the storage of oxidative metabolism and supplementary high-energy phosphate compound as cell helper factor, magnesium ion-ATP complex is the substrate of enzymatic reaction in muscle contraction and diastole process, magnesium ion is the cofactor of more than 260 kind of enzyme, required in oxidative metabolism, required in albumen synthesis, cell plasma stable state is required in maintaining, and maintains the normal function of ionic pump.
Due to the absorption of potassium cannot be carried out when lacking magnesium ion in vivo, in clinical practice while intravenous potassium supplement general magnesium supplement, but it is loaded down with trivial details to prepare potassium magnesium preparation program clinically, brings suitable inconvenience to work.
The neodoxy of clinical ischemic blood vessels-nerve-matrix protection is Mutiple Targets protection; so-called Mutiple Targets protection refers to and utilizes the effect separately of taurine, potassium ion and magnesium ion; namely it is respectively as EAA antagonists, ion channel modulators, anti-inflammatory drug, free radical scavenger, neurotrophic factor, Mild Hypothermal, Chinese medicine, gene therapeutic agents and stem-cell therapy agent etc. joint coordination treatment protection, and joint coordination protection is also played minimizing dosage and reduces the incidence rate of untoward reaction.
Current taurine, magnesia mixture, potassium agent are applied to as therapeutic agent separately and clinically appear in the newspapers; but market there are not above-mentioned three kinds of combination preparations possessing certain proportion to adjust or coordinate biological metabolism; also have no report three kinds of compositionss and be applied to disease such as ischemic injuries such as organ-tissue such as the treatment heart, brain etc., cause certain inconvenience to treatment and scientific research.
Taurine potassium magnesium compositions is by a certain proportion of taurine, magnesium, potassium combines, then traditional drug formulations technology can be adopted to be prepared into conventional pharmaceutical dosage forms, as injection (injection, injectable powder etc.), oral agents (tablet, capsule, oral liquid, granule, pill etc.), become a kind of feasible Novel clinical treatment heart, the organ-tissue ischemic injuries illness such as brain, particularly acute cerebral infarction, coronary heart disease, angina pectoris and migrainous effective medicine, also routine various food can be added into, in health product, as food additive or metallic element supplement, adjustment or coordination biological metabolism, application easily and effectively.
The compositions of taurine potassium magnesium makes it have effect of taurine, potassium ion and magnesium ion three simultaneously; it has good effect to preventing cardiovascular disease; through multiparty data displays such as clinical practices, said composition has obvious Synergistic therapeutical effect to organ-tissue ischemic injuries diseases such as acute cerebral infarction, coronary heart diseases and angina pectoris and migraine especially.Taurine potassium magnesium compositions preparation has the symptom of the headache of clear and definite alleviation acute cerebral infarction patients, dizzy, insomnia, to the atrial fibrillation of Treating Patients of Angina Pectoris, uncomfortable in chestly also to have greatly improved.And substantially increase absorbance and the utilization rate of potassium ion due to the cooperative effect of magnesium ion and potassium ion, and taurine is double herein does carrier, and suitable proportioning plays maximum biological effect, its kalium replenishment effect and regulate the metabolic function of human body very remarkable.
The invention also discloses a kind of preparation method of above-mentioned taurine potassium magnesium compositions, comprise the steps: 1) magnesium-containing compound, potassium-containing compound are dropped in reactor, latex A is made in the stirring that adds water; 2) by soluble in water for taurine be mixed with 5% taurine solution; 3) taurine solution is added latex A, react and make clear transparent solutions B in 4-6 hour, be warming up to 92-97 DEG C, be cooled to 89-90 DEG C after back flow reaction 0.5-1 hour and obtain product C; 4) drop in product C by active carbon, insulated and stirred uses the aseptic filtration of 0.22m microporous filter membrane after 0.5 hour; 5) by step 4) in be cooled to 0-5 DEG C of blowing after the filtrate decompression distillation and concentration that obtains; 6) by step 5) in the feed liquid centrifuge that obtains dry after at 93-95 DEG C, dry 1.5-2.5 hour after namely obtain taurine potassium magnesium compositions.This preparation method is simple to operate, and reaction condition is gentle, and transformation efficiency is higher, and target product yield is high.
Further, step 3) in the reaction temperature of taurine solution and latex A be 80 DEG C.At this temperature, reaction conversion ratio is relatively the highest.
Further, magnesium-containing compound is one or more in pharmaceutically acceptable magnesium hydroxide, magnesium carbonate, magnesium oxide, and described potassium-containing compound is one or more in pharmaceutically acceptable potassium hydroxide, potassium oxide, potassium carbonate.
A kind of preparation method of taurine potassium magnesium compositions effectively improves the yield of product; improve the content of effective ingredient; thus patient can obtain more effective ingredient when taking relatively less dosage medicine, being conducive to reducing side effects of pharmaceutical drugs, strengthening the safety of medication.
In sum; the invention has the beneficial effects as follows; a kind of taurine potassium magnesium compositions selects taurine and potassium ion, magnesium ion to combine; each composition is made to produce synergistic function; there is good curative effect effect to the organ-tissue such as the heart, brain ischemic injuries illness, and effectively can regulate the metabolic function of human body.
Detailed description of the invention
In order to make those skilled in the art person better understand the present invention program, carry out clear, complete description by the technical scheme in inventive embodiments below.
Embodiment 1
A kind of taurine potassium magnesium compositions, be made up of potassium ion, magnesium ion and taurine, wherein the mol ratio of potassium ion, magnesium ion and taurine is 2:1:4.
1, the preparation method of taurine potassium magnesium compositions
1) under room temperature, the magnesium hydroxide of the potassium hydroxide of 200mol, 100mol is dropped in reactor, add the water of 160L, start stirring and be warming up to 80 DEG C and keep 80 DEG C to be mixed with latex A;
2) under room temperature, the taurine of 400mol is dissolved in 100*10
4ml water, is mixed with 5% taurine solution of 5g/100ml;
3) added by the taurine solution prepared and be equipped with in the reactor of latex A, at 80 DEG C, stirring reaction 5 is little of latex A clear, is warming up to 92-97 DEG C after back flow reaction 0.5-1 hour and reacts completely, be cooled to 89-90 DEG C, obtain product C;
4) dropped in product C by 2kg active carbon, insulated and stirred uses the aseptic filtration of 0.22m microporous filter membrane while hot after 0.5 hour, filtrate is shifted in another reactor;
5) by step 4) in the filtrate decompression distillation and concentration that obtains be 400L to volume, be cooled to 0-5 DEG C of blowing;
6) by step 5) in after the feed liquid centrifuge that obtains dries, put into after baking oven dries 1.5-2.5 hour at 93-95 DEG C and obtain taurine potassium magnesium compositions.
2, experimental design
196 routine acute cerebral infarction patients are divided into 2 groups at random; treatment group is 98 routine patients; matched group is 98 routine patients; matched group presses apoplexy guide conventional therapy; treatment group, on basis of conventional therapy, by taurine potassium magnesium compositions 897mg, to add in 0.9% normal saline or 5% Glucose Liquid 500ml quiet; 1 times/day, two groups was all a course for the treatment of with 14 days.Two groups of patients respectively before the treatment and treat and evaluate for latter 14 days, statistical procedures, application X 2 test.
The course for the treatment of evaluation criteria:
A is almost recovered: functional impairment scoring reduces 91%-100%;
B marked improvement: functional impairment scoring reduces 46%-90%;
C is progressive: functional impairment scoring reduces 18%-45%;
D is unchanged: functional impairment scoring minimizing about 17%;
E worsens: functional impairment scoring reduces or increases more than 18%;
F is dead.
3, taurine potassium magnesium injection is to the observation of curative effect for the treatment of acute cerebral infarction
Table 1 liang group Clinical efficacy comparison (example)
Table 2 liang group event paresthesia epilepsy alleviation recovery normal time (on average) compares (my god)
The remarkable rate (be almost recovered+marked improvement) that can obtain treatment group from table 1 is 83.7%, is obviously better than 42.9% of matched group, and diversity significantly (significance,statistical P<0.05).Can show that from table 2 treatment group is obviously better than matched group.
Embodiment 2
A kind of taurine potassium magnesium compositions, be made up of potassium ion, magnesium ion and taurine, wherein the mol ratio of potassium ion, magnesium ion and taurine is 3:2:7.
1, the preparation method of taurine potassium magnesium compositions
1) under room temperature, the magnesium hydroxide of the potassium hydroxide of 300mol, 200mol is dropped in reactor, add the water of 270L, start and stir and be warming up to 80 DEG C and keep 80 DEG C to be mixed with latex A;
2) under room temperature, the taurine of 700mol is dissolved in 175*10
4ml water, is mixed with 5% taurine solution of 5g/100ml;
3) added by the taurine solution prepared and be equipped with in the reactor of latex A, at 80 DEG C, stirring reaction 5 is little of latex A clear, is warming up to 92-97 DEG C after back flow reaction 0.5-1 hour and reacts completely, be cooled to 89-90 DEG C, obtain product C;
4) dropped in product C by 5kg active carbon, insulated and stirred uses the aseptic filtration of 0.22m microporous filter membrane while hot after 0.5 hour, filtrate is shifted in another reactor;
5) by step 4) in the filtrate decompression distillation and concentration that obtains be 500L to volume, be cooled to 0-5 DEG C of blowing;
6) by step 5) in after the feed liquid centrifuge that obtains dries, put into after baking oven dries 1.5-2.5 hour at 93-95 DEG C and obtain taurine potassium magnesium compositions.
2, experimental design
240 routine Treating Patients of Angina Pectoris are divided into 2 groups at random; treatment group is 120 routine patients; matched group is 121 routine patients; matched group presses angina pectoris guide conventional therapy; treatment group, on basis of conventional therapy, by taurine potassium magnesium compositions 1033mg, to add in 0.9% normal saline or 5% Glucose Liquid 500ml quiet; 1 times/day, two groups was all a course for the treatment of with 14 days.Two groups of patients respectively before the treatment and treat and evaluate for latter 14 days, statistical procedures, application X 2 test.
The course for the treatment of evaluation criterion:
A is effective: angina pectoris attacks reduces 80%, and nitroglycerin consumption reduces 80%, and electrocardiogram recovers normal;
B is effective: angina pectoris attacks and nitroglycerin consumption reduce 50-80%, and electrocardiogram takes a turn for the better;
C is invalid: angina pectoris attacks and nitroglycerin reduce < 50%, and electrocardiogram is without change.
3, taurine potassium magnesium injection is to the observation of curative effect for the treatment of angina pectoris
Table 3 liang group Clinical efficacy comparison
A table 4 liang group treatment ECG change compares
Table 5 liang group event paresthesia epilepsy alleviation recovery normal time (on average) compares (my god)
The obvious effective rate that can obtain treatment group from table 3, table 4 is respectively 42.5%, 46.6%, is obviously better than 28.1% of matched group, 31.4%, and diversity significantly (significance,statistical P<0.05).Table 5 data can obtain treatment group and obviously be better than matched group.
Embodiment 3
A kind of taurine potassium magnesium compositions, be made up of potassium ion, magnesium ion and taurine, wherein the mol ratio of potassium ion, magnesium ion and taurine is 5:3:11.
1, the preparation method of taurine potassium magnesium compositions
1) under room temperature, the magnesium hydroxide of the potassium hydroxide of 500mol, 300mol is dropped in reactor, add the water of 320L, start and stir and be warming up to 80 DEG C and keep 80 DEG C to be mixed with latex A;
2) under room temperature, the taurine of 1100mol is dissolved in 275*10
4ml water, is mixed with 5% taurine solution of 5g/100ml;
3) added by the taurine solution prepared and be equipped with in the reactor of latex A, at 80 DEG C, stirring reaction 5 is little of latex A clear, is warming up to 92-97 DEG C after back flow reaction 0.5-1 hour and reacts completely, be cooled to 89-90 DEG C, obtain product C;
4) dropped in product C by 5kg active carbon, insulated and stirred uses the aseptic filtration of 0.22m microporous filter membrane while hot after 0.5 hour, filtrate is shifted in another reactor;
5) by step 4) in the filtrate decompression distillation and concentration that obtains be 600L to volume, be cooled to 0-5 DEG C of blowing;
6) by step 5) in after the feed liquid centrifuge that obtains dries, put into after baking oven dries 1.5-2.5 hour at 93-95 DEG C and obtain taurine potassium magnesium compositions.
2, experimental design
278 routine migraineurs are divided into 2 groups at random, and treatment group is 139 routine patients, and matched group is 140 routine patients; matched group presses neuralgia conventional therapy, treatment group on basis of conventional therapy, by oral for taurine potassium magnesium compositions tablet 1631mg; 3 times/day, two groups was all a course for the treatment of with 14 days.Two groups of patients respectively before the treatment and treat and evaluate for latter 14 days, statistical procedures, application X 2 test.
Efficacy determination pain scores method: adopt painless 0 point of international pain visual imitation assessment (visualanologuescale, VAS), light moderate pain l-6 divides, and severe pain 7-10 divides.
Index of assessment of curative effect: pain VAS score value × 100% before pain relief rate=pain VAS scoring changes values/treatment.
Therapeutic evaluation result:
A fully recovers: pain disappears completely;
B is effective: pain relief more than 25%;
C is invalid: pain relief is less than 25%.
3, taurine potassium magnesium injection is to the migrainous observation of curative effect for the treatment of
Table 6 liang group Clinical efficacy comparison
The cure rate that can obtain treatment group from table 6 is 87.8%, is obviously better than 49.3% of matched group, and diversity significantly (significance,statistical P<0.05).
Obviously, described embodiment is only a part of embodiment of the present invention, instead of whole embodiments.Based on the embodiment in the present invention, those of ordinary skill in the art, not making the every other embodiment obtained under creative work prerequisite, should belong to the scope of protection of the invention.
Claims (6)
1. a taurine potassium magnesium compositions, is characterized in that: described compositions is made up of potassium ion, magnesium ion and taurine.
2. taurine potassium magnesium compositions according to claim 1, is characterized in that: the mol ratio of the potassium ion in described compositions, magnesium ion and taurine is (1-8): (1-4): (3-16).
3. taurine potassium magnesium compositions according to claim 2, is characterized in that: the mol ratio of the potassium ion in described compositions, magnesium ion and taurine is 2:1:4.
4. a preparation method for the taurine potassium magnesium compositions as described in any one of claim 1-3, is characterized in that: comprise the steps:
1) magnesium-containing compound, potassium-containing compound are dropped in reactor, latex A is made in the stirring that adds water;
2) by soluble in water for taurine be mixed with 5% taurine solution;
3) taurine solution is added latex A, react and make clear transparent solutions B in 4-6 hour, be warming up to 92-97 DEG C, be cooled to 89-90 DEG C after back flow reaction 0.5-1 hour and obtain product C;
4) drop in product C by active carbon, insulated and stirred uses the aseptic filtration of 0.22m microporous filter membrane after 0.5 hour;
5) by step 4) in be cooled to 0-5 DEG C of blowing after the filtrate decompression distillation and concentration that obtains;
6) by step 5) in the feed liquid centrifuge that obtains dry after at 93-95 DEG C, dry 1.5-2.5 hour after namely obtain taurine potassium magnesium compositions.
5. the preparation method of taurine potassium magnesium compositions according to claim 4, is characterized in that: described step 3) in the reaction temperature of taurine solution and latex A be 80 DEG C.
6. the preparation method of taurine potassium magnesium compositions according to claim 4; it is characterized in that: described magnesium-containing compound is one or more in pharmaceutically acceptable magnesium hydroxide, magnesium carbonate, magnesium oxide, described potassium-containing compound is one or more in pharmaceutically acceptable potassium hydroxide, potassium oxide, potassium carbonate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510475025.1A CN105030748A (en) | 2015-08-05 | 2015-08-05 | Taurine potassium-magnesium compound and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510475025.1A CN105030748A (en) | 2015-08-05 | 2015-08-05 | Taurine potassium-magnesium compound and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105030748A true CN105030748A (en) | 2015-11-11 |
Family
ID=54438120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510475025.1A Pending CN105030748A (en) | 2015-08-05 | 2015-08-05 | Taurine potassium-magnesium compound and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105030748A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078170A1 (en) * | 2003-03-04 | 2004-09-16 | Nutrition Corp. Of America, Ltd. | Potassium taurate bicarbonate and ascorbate complexes |
| CN1827093A (en) * | 2005-04-29 | 2006-09-06 | 四川三民药业有限公司 | Taurine injection and method for preparing the same |
| CN1850063A (en) * | 2005-04-22 | 2006-10-25 | 北京华安佛医药研究中心有限公司 | Composition containing fibrate drug and taurine |
| CN101693679A (en) * | 2009-09-23 | 2010-04-14 | 黄再新 | Method for synthesizing magnesium taurate |
| CN103265560A (en) * | 2013-05-17 | 2013-08-28 | 上海中科高等研究院 | Gossypol/ cotton ketone derivative and preparation method thereof and application of derivative in anti-tumor medicament |
-
2015
- 2015-08-05 CN CN201510475025.1A patent/CN105030748A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078170A1 (en) * | 2003-03-04 | 2004-09-16 | Nutrition Corp. Of America, Ltd. | Potassium taurate bicarbonate and ascorbate complexes |
| CN1850063A (en) * | 2005-04-22 | 2006-10-25 | 北京华安佛医药研究中心有限公司 | Composition containing fibrate drug and taurine |
| CN1827093A (en) * | 2005-04-29 | 2006-09-06 | 四川三民药业有限公司 | Taurine injection and method for preparing the same |
| CN101693679A (en) * | 2009-09-23 | 2010-04-14 | 黄再新 | Method for synthesizing magnesium taurate |
| CN103265560A (en) * | 2013-05-17 | 2013-08-28 | 上海中科高等研究院 | Gossypol/ cotton ketone derivative and preparation method thereof and application of derivative in anti-tumor medicament |
Non-Patent Citations (1)
| Title |
|---|
| GWENELL MIXON: "Cardiovascular Research Ltd., Magnesium-Potassium Taurate, 60 Capsules", 《网址:HTTPS://WWW.AMAZON.COM/CARDIOVASCULAR-RESEARCH-LTD-MAGNESIUM-POTASSIUM-CAPSULES/DP/B00014GFO0》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008053728A1 (en) | Agent for promoting healing of living body | |
| CN103431392A (en) | Composite marine food for special dietary uses for diabetics | |
| EP0304986B1 (en) | The use of certain calcium-citrate-malate for the manufacture of a medicament for the treatment of osteoporosis | |
| CN101961347B (en) | Medicinal composition for treating cancer and use thereof | |
| CN105030748A (en) | Taurine potassium-magnesium compound and preparation method thereof | |
| KR20180002158A (en) | A composition for removing hangover comprising an herb extract including ginseng | |
| CN109965166A (en) | A kind of production method of lentinan drink | |
| CN101129956A (en) | Traditional Chinese medicine for treating rickets | |
| CN114617267A (en) | Reinforced composite bone peptide and preparation method and application thereof | |
| CN103800341B (en) | The combination medicine of anti-curing oncoma | |
| CN108434158A (en) | Application and drug of the 2-acetylamino-2-deoxy-D-glucose in preparing prevention atherosclerosis drug and health products | |
| CN109260235A (en) | A kind of application of composition in preparation prevention and treatment constipation drug or health care product | |
| CN100369616C (en) | Glossy ganoderma essence liquid and its usage | |
| CN108652010B (en) | Omega 3 quick solvent and preparation method thereof | |
| CN112971152A (en) | Intestinal tract exclusive active ginseng walnut peptide composition for improving human body circulation | |
| KR20030065964A (en) | Composition Containing Chaga Mushroom Extract as an Active Ingredient | |
| CN112294859A (en) | Anti-aging composition and preparation method thereof | |
| CN102657333B (en) | Blood pressure reducing and heart protecting composite nutrient and preparation method thereof | |
| CN1732974A (en) | Medicinal composition of fructose diphosphate sodium and magnesium salt | |
| KR100584214B1 (en) | The method of manufacturing potentiator using oyster shell powder | |
| Redfern | The Magnesium Manual: The Forgotten Mineral Every Body Needs: This Missing Mineral Could Hold The Key To Your Health | |
| CN110302266A (en) | A kind of hypoglycemic composition and preparation method thereof | |
| CN110584117A (en) | Physical strength recovery agent and preparation method thereof | |
| CN113413458A (en) | A pharmaceutical composition with antiaging effect, and its preparation method | |
| CN112841483A (en) | Novel enzyme thick pulp and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151111 |
|
| RJ01 | Rejection of invention patent application after publication |